Free Shipping On Orders Over $1,000!

PCANAP2 Polyclonal Antibody, ALEXA FLUOR® 488 Conjugated

Applications

  • WB

Reactivity

  • Rat

Predicted Reactivity

  • Human
  • Mouse
  • Dog
  • Cow
  • Sheep
  • Pig
  • Arabidopsis Thaliana
Overview
Catalog # bs-6568R-A488
Product Name PCANAP2 Polyclonal Antibody, ALEXA FLUOR® 488 Conjugated
Applications WB
Reactivity Rat
Predicted Reactivity Human, Mouse, Dog, Cow, Sheep, Pig, Arabidopsis Thaliana
Specifications
Conjugation ALEXA FLUOR® 488
Host Rabbit
Source KLH conjugated synthetic peptide derived from human PCANAP2
Immunogen Range 351-450/553
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 85414
Subcellular location Cell membrane
Synonyms IPCA 2; IPCA 8; IPCA6; PCANAP2; PCANAP6; PCANAP8; Prostate cancer associated gene 2; Prostate cancer associated gene 6; Prostate cancer associated gene 8; Prostate cancer associated protein 2; Prostate cancer associated protein 6; Prostate cancer associated protein 8; Prostate cancer-associated protein 6; Prostein; PRST; S45A3_HUMAN; Slc45a3; Solute carrier family 45 member 3.
Background PSA, prostate specific antigen, is the classic indicator for transformed pro-state tissue; however, in addition to being upregulated in prostate cancer, PSA is also upregulated in non-malignant conditions, such as benign prostatic hyperplasia. Prostein, also designated Prostate cancer-associated protein 6, is a prostate-specific, 553 amino acid transmembrane protein that is upregulated by androgens. It is considered a marker for prostate cells since it is expressed in all prostatic glandular cells as well as in normal and cancerous prostate tissues. Since it is able to elicit a tumor-directed cytotoxic T cell response, Prostein may be used as a target for the development of PSA- and T cell-based therapeutic strategies for prostate cancer.
Application Dilution
WB 1:300-5000